Celgene Corp (NASDAQ:CELG)

116.09
Delayed Data
As of May 22
 -0.11 / -0.09%
Today’s Change
74.52
Today|||52-Week Range
129.06
+3.78%
Year-to-Date
Healthcare Investment Opportunities for the Long Term
May 23 / MotleyFool.com
Celgene, Gilead, Netflix, Costco: Jim Cramer's Views
May 18 / TheStreet.com
Jim Cramer Answers Your Twitter Questions on Tesla, Jarden, Williams-Sonoma, Wayfair
May 21 / TheStreet.com
Is Gilead Sciences Its Own Worst Enemy?
May 17 / MotleyFool.com
Biotech Stock Roundup: Eleven Bio Slumps on Eye Drug Data, Achillion Signs Deal with ...
May 20 / Zacks.com
3 Safe Investments in Biotech (Relatively Speaking)
May 17 / MotleyFool.com
10 S&P 500 Companies to Have the Most Revenue Growth in 2015
May 20 / TheStreet.com
Here's Why Sorrento Therapeutics, Inc Shares Are Soaring
May 15 / MotleyFool.com
How Celgene Stock Is Breaking All the Rules
May 20 / MotleyFool.com
Stock Market News for May 15, 2015 - Market News
May 15 / Zacks.com
Agios Gains on Fast Track Status for Leukemia Drug AG-120 - Analyst Blog
May 19 / Zacks.com
Dividend Stocks: What You Need to Know
May 13 / MotleyFool.com
Celgene/Accelreon's Luspatercept Granted Fast Track Status - Analyst Blog
May 19 / Zacks.com
ETFs in Focus on Impressive Q1 Biotech Earnings - ETF News And Commentary
May 11 / Zacks.com
Stock Market News for May 19, 2015 - Market News
May 19 / Zacks.com
Stock Market News for May 11, 2015 - Market News
May 11 / Zacks.com
3 Biotechs That Are Worth Buying
May 18 / TheStreet.com
Biotechs' fees soar for drug development partnerships
May 05 / FT.com
Celgene's Crohn's Disease Drug Prompts Lingering Questions
May 18 / TheStreet.com
AstraZeneca forced to defend cancer drug deal with Celgene
Apr 24 / FT.com

To view my watchlist

Not a member yet?

Sign up now for a free account